Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2018

GlobalData's clinical trial report, “Wet (Neovascular / Exudative) Macular Degeneration Global Clinical Trials Review, H2, 2018" provides an overview of Wet (Neovascular / Exudative) Macular Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Wet (Neovascular / Exudative) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

Novartis AG

Bayer AG

Regeneron Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Pfizer Inc

Ophthotech Corp

Allergan Plc

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Ohr Pharmaceutical ...

Novartis AG

Bayer AG

Regeneron Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Pfizer Inc

Ophthotech Corp

Allergan Plc

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Ohr Pharmaceutical Inc

Bausch Health Companies Inc

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region ...

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 27

In Progress Trials by Phase 28

Clinical Trials by Trial Status 29

Clinical Trials by End Point Status 31

Subjects Recruited Over a Period of Time 32

Clinical Trials by Sponsor Type 33

Prominent Sponsors 34

Top Companies Participating in Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials 36

Prominent Drugs 38

Latest Clinical Trials News on Wet (Neovascular / Exudative) Macular Degeneration 40

Jul 02, 2018: Elsalys Biotech : New studies confirm anti-CD160 potential in ophthalmology 40

Jul 02, 2018: Opthea’s Phase 2b Wet AMD Clinical Trial Reaches Mid-Way Point of Patient Recruitment 41

Clinical Trial Profile Snapshots 42

Appendix 371

Abbreviations 371

Definitions 371

Research Methodology 372

Secondary Research 372

About GlobalData 373

Contact Us 373

Source 374

List of Tables

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2018* 8

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and ...

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region, 2018* 8

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 12

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 13

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries, 2018* 14

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 15

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 16

Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2018* 17

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20

Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2018* 22

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase, 2018* 27

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 28

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 33

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

List of Figures

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials ...

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 11

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 12

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 13

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 14

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 15

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 16

Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, G7 Countries (%), 2018* 17

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 19

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20

Proportion of Wet (Neovascular / Exudative) Macular Degeneration to Ophthalmology Clinical Trials, E7 Countries (%), 2018* 22

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Phase (%), 2018* 27

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 28

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 33

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

GlobalData Methodology 372

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports